Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

Across a broad range of human cancers, gain-of-function mutations in RAS genes (HRAS, NRAS, and KRAS) lead to constitutive activity of oncoproteins responsible for tumorigenesis and cancer progression. The targeting of RAS with drugs is challenging because RAS lacks classic and tractable drug bindin...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Daolin, Kroemer, Guido, Kang, Rui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489073/
https://www.ncbi.nlm.nih.gov/pubmed/34607583
http://dx.doi.org/10.1186/s12943-021-01422-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489073/
https://www.ncbi.nlm.nih.gov/pubmed/34607583
http://dx.doi.org/10.1186/s12943-021-01422-7

Ejemplares similares